I agree that this site is using cookies. You can find further informations here.
X
Penazzato, M.
~ 100  results:
Search for persons X
?
1

Choice of Antiretroviral Drugs for Postexposure Prophylaxis..:

Penazzato, M. ; Dominguez, K. ; Cotton, M...
Clinical Infectious Diseases.  60 (2015)  suppl 3 - p. S177-S181 , 2015
Link: https://doi.org/10.1093/..
 
?
2

Factors Determining Survival and Retention among HIV-Infect..:

Massavon, W. ; Barlow-Mosha, L. ; Mugenyi, L....
ISRN AIDS.  2014 (2014)  - p. 1-13 , 2014
Link: https://doi.org/10.1155/..
 
?
3

Epstein-Barr Virus Load in Children Infected With Human Imm..:

Petrara, M. R. ; Penazzato, M. ; Massavon, W....
Journal of Infectious Diseases.  210 (2014)  3 - p. 392-399 , 2014
Link: https://doi.org/10.1093/..
 
?
4

Development of Antiretroviral Resistance in Children With H..:

Fitzgerald, F. ; Penazzato, M. ; Gibb, D.
Journal of Infectious Diseases.  207 (2013)  suppl 2 - p. S85-S92 , 2013
Link: https://doi.org/10.1093/..
 
?
5

Use of age and CD4 cell count as criteria for identificatio..:

Lodi, S ; Penazzato, M ; Jordan, M.
Journal of the International AIDS Society.  15 (2012)  S4 - p. 1-1 , 2012
Link: https://doi.org/10.7448/..
 
?
6

Italian consensus statement on paediatric HIV infection:

Giaquinto, C. ; Penazzato, M. ; Rosso, R....
Infection.  38 (2010)  4 - p. 301-319 , 2010
Link: https://doi.org/10.1007/..
 
?
7

COVID-19 and MIS-C treatment in children—results from an in..:

Donà, D ; Minotti, C ; Masini, T...
https://discovery.ucl.ac.uk/id/eprint/10177861/1/s00431-023-05179-7.pdf.  , 2023
Link: https://discovery.ucl.ac..
 
?
8

Assessing the Appropriateness of Formulations on the WHO Mo..:

Walsh J ; Masini T ; Huttner B. D...
info:eu-repo/semantics/altIdentifier/pmid/35335850.  , 2022
Link: https://hdl.handle.net/2..
 
?
9

Cost-effectiveness of Routine Provider-Initiated Testing an..:

Stanic, T ; McCann, N ; Penazzato, M...
https://discovery.ucl.ac.uk/id/eprint/10141939/1/Stanic%20et%20al.%20CEA%20of%20provider%20initiated%20HIV%20testing%20of%20children%20%28OPID%202021%29.pdf.  , 2022
Link: https://discovery.ucl.ac..
 
?
10

WHO target product profiles for TB preventive treatment:

Boon, S Den ; Lienhardt, C ; Zignol, M...
qt4ch1m65r.  , 2022
Link: https://escholarship.org..
 
?
11

Optimizing infant HIV diagnosis with additional screening a..:

Dunning, L ; Gandhi, AR ; Penazzato, M...
https://discovery.ucl.ac.uk/id/eprint/10119709/1/Dunning%20et%20al.%20Optimising%20EID%20%28JIAS%202020%29.pdf.  , 2021
Link: https://discovery.ucl.ac..
 
?
12

Chronic comorbidities in children and adolescents with peri..:

Frigati, LJ ; Ameyan, W ; Cotton, MF...
doi:10.1016/s2352-4642(20)30037-7.  , 2020
Link: https://doi.org/10.1016/..
 
?
13

The HIV drug optimization agenda: promoting standards for e..:

Rojo, P ; Carpenter, D ; Venter, F..
https://discovery.ucl.ac.uk/id/eprint/10110255/1/jia2.25576.pdf.  , 2020
Link: https://discovery.ucl.ac..
 
?
14

Hepatitis B virus infection in children and adolescents:

Indolfi, G ; Easterbrook, P ; Dusheiko, G...
https://discovery.ucl.ac.uk/id/eprint/10073087/10/Thorne%20HBV%20Indolfi%20Easterbrook%20rev%202%20plain%20text.pdf.  , 2019
Link: https://discovery.ucl.ac..
 
?
15

A global research agenda for adolescents living with HIV:

Armstrong, A ; Nagata, J ; Vicari, M...
doi:10.1097/qai.0000000000001744.  , 2019
Link: https://doi.org/10.1097/..
 
1-15